Compare VAL & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VAL | PTCT |
|---|---|---|
| Founded | 1975 | 1998 |
| Country | Bermuda | United States |
| Employees | 5070 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.7B |
| IPO Year | N/A | 2006 |
| Metric | VAL | PTCT |
|---|---|---|
| Price | $75.40 | $83.64 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 17 |
| Target Price | $64.00 | ★ $80.65 |
| AVG Volume (30 Days) | 846.9K | ★ 1.9M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,734,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.76 | $17.70 |
| P/E Ratio | $16.22 | ★ N/A |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $41.23 | $43.18 |
| 52 Week High | $114.12 | $87.50 |
| Indicator | VAL | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 30.68 | 68.32 |
| Support Level | $47.57 | $73.41 |
| Resistance Level | $104.05 | $87.50 |
| Average True Range (ATR) | 3.04 | 3.06 |
| MACD | -1.03 | 1.01 |
| Stochastic Oscillator | 6.09 | 79.99 |
Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.